Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2020

Competitive tight-binding inhibition of VKORC1 underlies warfarin
dosage variation and antidotal efficacy
Shuang Li
Washington University School of Medicine in St. Louis

Shixuan Liu
Washington University School of Medicine in St. Louis

Xiaoran Roger Liu
Washington University in St. Louis

Mengru Mira Zhang
Washington University in St. Louis

Weikai Li
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Li, Shuang; Liu, Shixuan; Liu, Xiaoran Roger; Zhang, Mengru Mira; and Li, Weikai, ,"Competitive tight-binding
inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy." Blood Advances. 4,10. .
(2020).
https://digitalcommons.wustl.edu/open_access_pubs/9204

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

REGULAR ARTICLE

Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage
variation and antidotal eﬃcacy

1
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO; and 2Department of Chemistry, Washington University in
St. Louis, St. Louis, MO

Key Points

• Tight-binding inhibition
underlies warfarin dosage variations.
• Vitamin K antidote
competes off warfarin
tightly bound to
VKORC1, whose rescued activity contributes to the reversal of
anticoagulation.

Dose control of warfarin is a major complication in anticoagulation therapy and overdose is
reversed by the vitamin K antidote. Improving the dosage management and antidotal eﬃcacy
requires mechanistic understanding. Here we ﬁnd that effects of the major predictor of
warfarin dosage, SNP 21639 G.A, follow a general correlation that warfarin 50% inhibitory
concentration decreases with cellular level of vitamin K epoxide reductase (VKORC1),
suggesting stoichiometric inhibition. Characterization of the inhibition kinetics required the
use of microsomal VKORC1 with a native reductant, glutathione, that enables effective
warfarin inhibition in vitro. The kinetics data can be ﬁtted with the Morrison equation,
giving a nanomolar inhibition constant and demonstrating that warfarin is a tight-binding
inhibitor. However, warfarin is released from puriﬁed VKORC1-warfarin complex with
increasing amount of vitamin K, indicating competitive inhibition. The competition occurs
also in cells, resulting in rescued VKORC1 activity that augments the antidotal effects of
vitamin K. Taken together, warfarin is a competitive inhibitor that binds VKORC1 tightly and
inhibits at a stoichiometric (1:1) concentration, whereas exceeding the VKORC1 level results
in warfarin overdose. Thus, warfarin dosage control should use VKORC1 level as a major
indicator, and improved antidotes may be designed based on their competition with
warfarin.

Introduction
Warfarin is an oral anticoagulant widely used to treat and prevent thromboembolic diseases.1 Because
warfarin has a narrow therapeutic index, effective dosing of this drug requires frequent anticoagulation
monitoring and dose adjustments. Underdosing warfarin increases the risk of thrombosis in patients,
whereas overdosing often leads to major, even fatal bleeding. As the antidote for the overdose, vitamin K
is generally given to restore the coagulation. The management of warfarin dosage is further complicated
by its wide interindividual variation.2,3 The most important predictor of warfarin dosage is the genotype of
vitamin K epoxide reductase (VKORC1),4-9 whose promoter region contains a single nucleotide
polymorphism (SNP) 21639 G.A that accounts for ;25% of the interpatient variability.6,7,10 This SNP
lowers the messenger RNA (mRNA) and protein levels of VKORC1, and patients carrying this SNP
require lower warfarin dosage.8
As the target of warfarin, VKORC1 supports blood coagulation through the vitamin K cycle. This cycle
occurs in the endoplasmic reticulum (ER) and begins with the g-carboxylation of selected coagulation
factors, a posttranslational modification required for their activity. The carboxylase activity is driven by the
epoxidation of vitamin K hydroquinone (KH2). To regenerate the hydroquinone, VKORC1 reduces the
vitamin K epoxide (KO) first to vitamin K quinone (K) and then to KH2. These reductase activities are
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maintained by reducing molecules in the ER. The warfarin inhibition
of these activities hinders the production of functional coagulation
factors, thereby decreasing blood clotting.

Here, we reproduce the effects of SNP 21639 G.A by using the
cellular carboxylation assay.17 The assay allows us to identify
a general correlation that warfarin IC50 increases with VKORC1
level. We found a similar correlation for VKORC1 in microsomes
and as purified protein, which become warfarin sensitive with the use of
GSH, the major reductant in the ER. Warfarin inhibition follows tightbinding kinetics and is competitive with vitamin K, a profound
mechanism that underlies warfarin dosing and antidoting.

Methods
Cloning and transfection
To implement SNP 21639 G.A for the cellular assay, the promoter
sequence of VKORC1 (c.-1800 to c.-0) was polymerase chain
reaction (PCR)-amplified from the genomic DNA prepared from
Huh7 cells. The PCR fragment was cloned into a pBudCE4.1 vector
and placed before the VKORC1 complementary DNA (cDNA). The
coding sequence includes a C-term Flag tag and an ER retention
signal.13,18 The G.A change in the promoter region was introduced
by site-directed mutagenesis by using Quikchange. The constructs
were transfected into a HEK293 cell line that has endogenous
VKORC1 and VKORC1L1 genes knocked out (DKO) and has an
introduced chimeric FIXgla-Protein C (FIXgla-PC) gene as the
g-carboxylation reporter.13,18 The FIXgla-PC DKO cells on 24-well
plates were transfected with 0.6 mg DNA and grown for 48 hours.
Subsequently, the cell media containing the secreted FIXgla-PC was
used for the carboxylation assay.
To change VKORC1 levels systematically, variable amounts (0-1.5 mg)
of the pBudCE4.1 vector containing PCMV6-controlled VKORC1
and an empty vector (to make 1.5 mg total DNA) were cotransfected
by using lipofectamine 3000 into the FIXgla-PC DKO cells on 24-well
plates.

Cellular assay of warfarin IC50
The cellular carboxylation assay was performed as previously
described.13,18 To measure the IC50 levels of warfarin, the cells
26 MAY 2020 x VOLUME 4, NUMBER 10

Quantification of mRNA and protein levels
The mRNA from transfected cells was extracted using TRIZOL.
Reverse transcriptase-PCR of the VKORC1 mRNA was performed
on a Strategene Mx3005P system using a SYBR green RNA-to-CT
kit (Thermo). Glyceraldehyde-3-phosphate dehydrogenase was
used as an internal control.
For in-cell enzyme-linked immunosorbent assay (ELISA), cells were
fixed with methanol for 2 hours at 220°C and permeabilized in Trisbuffered saline buffer containing 20 mM Tris pH 7.5, 150 mM NaCl,
and 0.1% Tween 20. ELISA was carried out using mouse anti-flag
M2 (Sigma F3165) and horseradish peroxidase-conjugated goatanti-mouse (Sigma A4416) antibodies.
For quantitative western blot, mouse anti-flag M2 and anti-VKORC1
antibodies (Thermo PA560093) were used. The band intensities
were quantified by Image J.

VKORC1 expression
VKORC1 with a fused split green fluorescent protein was cloned
into a modified pPICZ-B expression vector and selected by
expression level.24 The cells were grown in buffered minimal
glycerol media at 30°C for 20 hours, and protein expression was
induced by 0.7% methanol for 48 hours at 25°C.

Preparation of ER-enriched microsomes
Frozen Pichia cells were broken with a ball mill (Retsch) followed by
sonication. After removal of cell debris, the supernatant was
centrifuged at 138 000g for 1 hour to collect crude microsomes.
Purification of microsomes followed a reported protocol,12 with
a modification that 35% and 60% sucrose (w/v) were used for step
gradient. The enriched ER membranes were resuspended in
150 mM KCl and 50 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid pH 7.5. Concentration of total proteins was determined by using a bicinchoninic acid assay.

Warfarin inhibition of microsomal VKORC1
Microsomes at different concentrations were preincubated with 11
concentrations of warfarin for 30 minutes on ice. VKORC1 catalysis
was initiated in 500 mL buffer containing 40 mM GSH, 5 mM KO,
150 mM KCl, and 200 mM N-2-hydroxyethylpiperazine-N9-2ethanesulfonic acid pH 7.5. The reaction was carried out at
30°C for 2 hours and analyzed by high-performance liquid
chromatography.25 The KO to K conversion was confirmed by
liquid chromatography–mass spectrometry (LC-MS) and extractedion chromatogram (supplemental Figure 1). To compare the effect
of different reductants, GSH was substituted by a mixture of 60 mM
GSH and 20 mM GSSG or by 6.25 mM DTT.

Purification of VKORC1-warfarin complex
Broken Pichia cells were resuspended in a buffer containing
150 mM NaCl, 25 mM Tris-HCl pH 8.0, and 1 mM warfarin at 4°C
for 20 minutes. Subsequently, 3% n-dodecyl-b-d-maltopyranoside
was added to solubilize the membranes for 3 hours at 4°C. After
centrifugation, the supernatant was purified through metal-affinity
WARFARIN DOSING AND ANTIDOTING MECHANISM
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VKORC1 activity was traditionally analyzed in vitro, using dithiothreitol (DTT) to mimic the reducing equivalent in cells. In the
presence of DTT, however, the 50% inhibitory concentration (IC50)
of warfarin is at millimolar concentration,11,12 which is much
higher than the nanomolar therapeutic range of warfarin.13-17 This
large discrepancy is probably because DTT reduces VKORC1
almost completely, whereas warfarin preferably inhibits oxidized
VKORC1.18,19 Indeed, this membrane oxidoreductase is primarily
oxidized in cells, with ;40% of it in the fully oxidized state and
50% in partially oxidized state.18 The oxidized status of VKORC1
is maintained in the ER, which contains a redox buffer comprising
a high concentration (;15 mM) of reduced glutathione (GSH)
and oxidized glutathione (GSSG).20-22 Because the DTT-driven
assays in vitro are conducted under nonphysiological conditions,
cellular assays were later developed to measure the VKORC1
activity that promotes carboxylation of introduced coagulation
factors.13,16,17,23 The IC50 of warfarin in cells is found to be in the
nanomolar range, consistent with its therapeutic range. Thus, the
cellular systems provide a valid model to study the warfarin
dosage.

expressing different amounts of VKORC1 were treated with
warfarin at 11 different concentrations. This concentration range
was optimized according to the warfarin response at different
VKORC1 expression levels. IC50 levels were analyzed by using
GraphPad Prism.
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Figure 1. Cellular effects of SNP 21639 G>A. (A) Vector construction. VKORC1 promoter with the SNP 21639 G.A is placed before the VKORC1 cDNA in the
pBudCE4.1 vector for carboxylation assay. The vector carries a luciferase gene to control for transfection efficiency. (B) Warfarin inhibition of the SNPs. Inhibition curves (left)
relative IC50 level (right). (C) Cellular mRNA level of the SNPs. (D) Cellular protein level of the SNPs. The western blots use the anti-VKORC1 (left) and anti-flag (right)
antibodies, with b-actin level (bottom) as controls. (E) Protein level comparison by in-cell ELISA. All error bars represent 3 repeats. **P , .01 by Student t test.

chromatography with 15 mM and 250 mM imidazole in washing and
elution buffers containing 150 mM NaCl, 20 mM Tris pH 8.0, 0.2%
n-dodecyl-b-d-maltopyranoside, and 0.1 mg/mL POPC/POPE/
POPG mixture (3:1:1). The protein was further purified through
a Superdex 200 column (24 mL) in a buffer containing 150 mM
NaCl, 20 mM Tris pH 8.0, 0.05% lauryl maltose neopentyl glycol,
and the lipid mixture. The VKORC1 protein in the mixed micelles
were concentrated to 40 mg/mL for activity assay.

Fluorometric-based assay of KO and K
reductase activities
The reaction catalyzed by purified VKORC1-warfarin complex was
initiated in a buffer containing 20 mM KO or 50 mM K, 40 mM GSH,
0.1% lauryl maltose neopentyl glycol, 0.1 M NaCl, and 20 mM Tris
pH 7.6. The KH2 fluorescence was detected with excitation at
248 nm and emission at 430 nm.26,27

Results
Reproducing the effects of SNP 21639 G>A in cells
To test the effect of SNP 21639 G.A in a cellular system, we
cloned the entire VKORC1 promoter (c.-1800 to c.-0) from human
genome into the pBudCE4.1 vector and placed the promoter
before the cDNA coding sequence of VKORC1 (Figure 1A). The
same amount of the plasmids carrying the G or A variation were
transfected into the FIXgla-PC DKO cells,13 and g-carboxylation
level of secreted FIXgla-PC was measured under different warfarin
2204
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concentrations. The IC50 of warfarin dose-response curve was
found to be lowered by about 1.6-fold with the 21639 G.A
change (Figure 1B), similar to the corresponding dose change in
patients.4-8 To further compare with the clinical observations, we
quantified the mRNA level of transfected cells by quantitative PCR
and their protein level by western blot and in-cell ELISA. In addition,
the transfection efficiency was determined by luciferase activity; the
pBudCE4.1 vector contains a luciferase gene for this purpose. With
DNA transfection at nearly the same level (supplemental Figure 2),
the G.A change lowers the cellular mRNA level of VKORC1 by
2.1-fold (Figure 1C). The lowered protein levels are measured to be
approximately 1.7- and 2.1-fold with western blot by using the antiVKORC1 and anti-flag antibody, respectively (Figure 1D). Consistently, in-cell ELISA using the anti-flag antibody shows a twofold
change of protein level (Figure 1E). Overall, introducing the
promoter variation in the cellular assay system generates similar
effects as SNP 21639 G.A in vivo.4-8 The lowered VKORC1
levels in cells result in the lowered warfarin IC50, which may manifest
as lowered warfarin dosage in patients.

Warfarin is distinct from typical inhibitors
To further understand the correlation, we systematically varied the
VKORC1 levels by changing the transfection amount of pCMV6
promoter controlled VKORC1, a construct designated for the
g-carboxylation assay, into the FIXgla-PC DKO cells.13 As expected,
western blot (Figure 2A) and in-cell ELISA (Figure 2B) showed
that higher amounts of DNA transfection result in higher VKORC1
26 MAY 2020 x VOLUME 4, NUMBER 10
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Figure 2. General correlation between warfarin IC50 and VKORC1 levels. (A) Quantification of cellular VKORC1 levels. Endogenous VKOR and VKOR transfection in
various amounts (top) and purified VKORC1 protein in various amounts (bottom). Anti-VKORC1 antibody was used for the western blots, which were developed simultaneously
to allow direct comparison and quantification. (B) In-cell ELISA quantification of the protein level of transfected VKORC1. (C) Warfarin inhibition curves with different amounts
of transfected VKORC1. (D) Correlation between warfarin IC50 (from panel C) and VKORC1 protein level. ELISA reading of the protein level is converted from DNA transfection amount (from panel B). Error bars are estimated from the inhibition curves.

expression level. With elevated protein levels, the IC50 of warfarin also
increases (Figure 2C). The correlations between DNA transfection,
VKORC1 level, and warfarin IC50 are nearly linear (Figure 2B,D).
Thus, there is a general correlation between warfarin IC50 and
VKORC1 level, explaining the effects of SNP 21639 G.A.
Given this linear correlation, the actual IC50 of warfarin in human
cells should largely be dependent on the endogenous VKORC1
level. Because the cellular activity of endogenous VKORC1 is
difficult to measure, we used a transfected VKORC1 level similar to
that in Huh7 cells and HEK293 cells, which are derived from human
liver and kidney, respectively; although the liver is where the warfarin
inhibition of g-carboxylation of coagulation factors occurs, all the
cellular assay systems established to date used HEK293.13,16,17,23
Western blot using an anti-VKORC1 antibody showed that the
endogenous VKORC1 levels in HEK293 and Huh7 cells are similar
to that of 30 ng transfected VKORC1 in FIX-PC DKO HEK293 cells
26 MAY 2020 x VOLUME 4, NUMBER 10

(Figure 2A). The amount of VKORC1 protein in these cells is further
quantified by comparing with purified VKORC1 protein (see the
following section) at varying concentrations, which are blotted
under the same conditions (Figure 2A, bottom). After dividing the
protein amount by cell density, we estimated the endogenous level
of VKORC1 protein to be about 104 copies in 1 cell, corresponding
to the VKORC1 concentration at the nanomolar range. Remarkably,
warfarin IC50 at the endogenous VKORC1 level (estimated from
30 ng transfected DNA) is approximately 0.6 nM (Figure 2C). The
proximity between the warfarin IC50 and VKORC1 concentration
argues that warfarin is not a typical inhibitor, for which the IC50 must
be much larger (.1000 times) than the enzyme concentration.28

GSH reduction enables effective warfarin inhibition
in vitro
The cellular assay is limited in its ability to characterize enzyme
inhibition kinetics precisely. To overcome this problem, we studied
WARFARIN DOSING AND ANTIDOTING MECHANISM
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Figure 3. Microsomal VKORC1 maintains warfarin sensitivity with glutathione reduction. (A) Warfarin inhibition curves of VKORC1 reduced by DTT, GSH, and
GSH/GSSG. Error bars are from 3 repeats. (B) Relative IC50 levels. Error bars are calculated from Morrison fitting of the inhibition curves in panel A. The IC50 levels observed
with DTT, GSH, and GSH/GSSG are 2.4 6 0.76 mM, 52 6 12 nM, and 82 6 7 nM, respectively.

the inhibition kinetics of warfarin against VKORC1 in ER-enriched
microsomes, which afford a native-like membrane environment
in vitro. However, traditional inhibition assays using microsomes or
detergent-dissolved cells, with DTT as the reductant, showed that
the IC50 of warfarin is in the micromolar range. Because DTT is
known to be a nonphysiological reductant, we substituted it with
GSH, the major reductant in the ER, to drive VKORC1 catalysis
in vitro. For comparison, we also included GSH/GSSG (3:1), which
provides a similar redox potential as in the ER. With these different
reducing equivalents, we analyzed the warfarin inhibition of KO to
K conversion by microsomal VKORC1. Remarkably, VKORC1
becomes highly sensitive to warfarin inhibition in presence of GSH
or GSH/GSSG (Figure 3A). At a fixed microsomal VKORC1
concentration, the IC50 levels with GSH and GSH/GSSG are
52 nM and 82 nM, respectively (Figure 3B). In comparison, the IC50
with DTT is 2.4 mM. Thus, using GSH as the reductant increases
the warfarin sensitivity by 46-fold. This large improvement indicates
that the artificially high IC50 observed in previous in vitro studies is
due to the use of DTT. In contrast, in vitro assay driven by the native
reductants, GSH or GSH/GSSG, shows IC50 at the nanomolar
range, as observed in cellular systems and in patients.4-10,13,16,17,23

Warfarin shows tight-binding kinetics with
microsomal VKORC1
To determine the inhibition kinetics, we measured the IC50 of
warfarin with the GSH reductant and at different VKORC1 protein
concentrations, which were achieved by adding different amounts
of microsomes in the reaction buffer (Figure 4A). The actual
VKORC1 concentrations was estimated from quantitative western
blots using purified protein as the standard (Figure 4B). Plotting the
IC50 levels of warfarin against the enzyme concentrations shows
a linear correlation (Figure 4C), which fits to a general equation for
enzyme inhibition kinetics28: IC50 5 1/2 [E] 1 Kiapp. The observed
slope is close to 0.5, indicating that the [E] estimated from
quantitative western analysis is close to the effective [E] in the
reaction. The intercept gives an apparent inhibition constant (Kiapp)
of about 20 nM, which is much lower than the warfarin or VKORC1
2206
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concentration used in the reaction. Thus, most of the warfarin
inhibitor is bound to the VKORC1 enzyme. Consequently, the
assumption of a largely free inhibitor in typical enzymology studies is
no longer valid.28 This situation is deemed as tight-binding inhibition,
as the VKORC1 enzyme binds warfarin with very high affinity.
The inhibition data could be fitted by the Morrison equation that
defines tight-binding inhibition (Figure 4A).29 The Kiapp estimated
from the Morrison equation ranges from 20 to 60 nM for the
different inhibition curves, similar to the Kiapp obtained from the IC50
correlation. Extrapolation from linear region of the Morrison curves
gives an accurate measure of the effective enzyme concentration28
(Figure 4D), which is close to the estimation from the quantitative
western blot analysis (Figure 4B). Importantly, at different enzyme
concentrations, the corresponding IC50 levels are always approximately one-half (Figure 4C). Thus, a stoichiometric amount of
warfarin (1:1) is sufficient to inhibit VKORC1.

Vitamin K antidote competes off tightly
bound warfarin
Using a purified system avoids potentially interfering factors in
cellular and microsomal systems. However, VKORC1 quickly loses
activity during protein purification in a detergent solution, underscoring the difficulty of studying this intramembrane enzyme.27 To
stabilize this protein,18 we added saturating amount of warfarin to
VKORC1 before membrane solubilization. With warfarin bound
to VKORC1 in an essentially irreversible manner,30,31 we could purify
the protein in the amount of milligrams and to near homogeneity
(supplemental Figure 3A). The molar ratio between VKORC1 and
warfarin should be 1:1 after size-exclusion chromatography,
because free warfarin was removed and free VKORC1 protein
was lost owing to instability. We varied the concentration of this
VKORC1-warfarin complex and measured the apparent IC50
of warfarin. The assay was conducted with 20 mM KO or 50 mM
K as the substrate and GSH as the reducing equivalent,
and fluorescence of the KH2 product was monitored.26,27 The
inhibition curves show that the apparent IC50 increases with the
complex concentration in presence of K (Figure 5A) or KO
26 MAY 2020 x VOLUME 4, NUMBER 10
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(supplemental Figure 3B). Thus, similar to the microsomal
VKORC1, the purified VKORC1-warfarin appears to follow
tight-binding kinetics. Interestingly, the purified VKORC1-warfairn
complex regains activity in presence of GSH and substrates,
indicating that the tightly bound warfarin is released from VKORC1
during catalysis.
As the antidote for warfarin overdose, vitamin K is given to patients
in large amount (1-10 mg) that potentially can compete off bound
warfarin from VKORC1. If this competition exists, increasing
concentrations of K should release more warfarin from VKORC1
and result in higher regained activity. Indeed, we found that vitamin
K at 0.4, 4, and 40 mM concentration results in increasingly restored
VKORC1 activity (Figure 5B). In presence of 30 nM VKORC1warfarin complex, 4 mM of K is sufficient to restore the maximum
activity level (as 40 mM of K). In contrast, when 10X more complex
(300 nM) is used, 4 mM of K becomes insufficient to fully restore
26 MAY 2020 x VOLUME 4, NUMBER 10

activity. This discrepancy is because more warfarin-bound complexes requires more vitamin K for the competition to restore
VKORC1 activity.
To confirm these in vitro observations, we investigated the
competition between vitamin K and warfarin in FIXgla-PC DKO
cells. Using the carboxylation assay, we found that warfarin IC50
increases with K concentration in a roughly linear fashion (Figure
5C-D), consistent with the competition mechanism. Comparison of
the inhibition curves show that, at the same warfarin concentration,
the carboxylation activity is inhibited at low K concentration but
rescued at high K concentration, as occurs during the antidotal
treatment of warfarin overdose. For instance, the carboxylation
activity at 5 nM K is inhibited at a plateau by 0.1 nM warfarin. At the
same warfarin concentration, however, 4 mM K rescues ;80% of
the carboxylation activity, which comprises ;50% from restored
VKORC1 and 30% from an additional reductase that has been
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Figure 5. Vitamin K competition releases tightly bound warfarin. (A) Warfarin inhibition curves with different concentrations of purified VKORC1-warfarin complex and
with K as the substrate. (B) Relative VKORC1 activity at varying concentrations of VKORC1-warfarin and K. (C) Warfarin inhibition of cellular activity of transfected VKORC1
under different K concentrations. The dashed line illustrates that, under the same warfarin concentration, VKORC1 activity is inhibited at 5 nM K but retained at 4 mM K. The
double arrow indicates relative activity of the unknown enzyme (not inhibited by warfarin) at high warfarin concentration with 4 mM K. (D) Correlation between cellular warfarin
IC50 and K concentration (from panel C). (E) Relative activities of VKORC1 and the unknown enzyme in absence of warfarin. The total carboxylation activity from VKORC1 and
the unknown enzyme is measured with endogenous level of VKORC1 (30 ng; Figure 2A) transfected into DKO cells. Activity of the unknown enzyme is measured without the
VKORC1 transfection, and subtraction of this activity from the total activity gives the VKORC1 activity. The curves show Michaelis-Menten fittings, and the dashed line illustrates that activity of the unknown enzyme is considerably lower than that of VKORC1 at a high K concentration (4 mM).
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Warfarin has been long thought to bind at the active site of
VKORC1 19,33 and therefore should compete with substrate
binding. However, warfarin shows noncompetitive inhibition kinetics
in vitro,12,34,35 puzzling the field for decades. Because DTT, an
artificial reductant, was used in previous studies, we replaced it with
GSH in these studies to create a reductive environment similar to
that in the ER. With GSH driving the VKORC1 catalysis, the K
substrate becomes competitive against warfarin, consistent with
the notion that warfarin binds at the active site. With the
competition, the tightly bound warfarin is released and VKORC1
activity is restored. Vitamin K may have a similar competition effect
in vivo when given as a warfarin antidote, in addition to the
commonly accepted route that another reductase can reduce
vitamin K to the hydroquinone form.23,32 According to results from
the cellular model, VKORC1 released from bound warfarin may
contribute more to the restored carboxylation activity than this
unknown reductase does (Figure 5C), affording a new understanding of the antidotal process.
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Figure 6. Mechanism and implication of warfarin tight-binding inhibition.
(A) Difference between GSH and DTT. (Top) GSH maintains the native conformation of VKORC1 required for the tight binding of warfarin. This conformation is
stabilized by a disulfide bond in the partially oxidized state.18 (Bottom) DTT fully

The tight binding of warfarin to VKORC1 is maintained in presence
of GSH, which has key differences from DTT (Figure 6A). GSH is
a monothiol that passes 1 electron at a time and only reduces 1
cysteine in a disulfide bond. Thus, GSH can maintain the partially
oxidized state of VKORC1 (with 1 disulfide bond), a major form
found in the cellular environment.18 In contrast, DTT is a dithiol that
delivers 2 electrons and completely reduces a disulfide bond. In
addition, DTT is smaller than GSH and is membrane permeable.
Thus, DTT can reduce all the disulfide bonds in VKORC1, including
a disulfide buried in the membrane. The native protein conformations of VKORC1, however, are presumably held together by 1 or 2
disulfide bonds. Reducing all the disulfide bonds by DTT disrupts
the native conformations, thereby abolishing the tight binding of
warfarin. Moreover, the redox potentials of GSH/GSSG (2160 mV)
and GSH (2240 mV) are much higher than that of DTT (2325 mV).
Redox equilibrium under these high potentials maintains the partially
oxidized state of VKORC1 in solution, as occurring in cells. It
appears that the proper redox state and native conformation of
VKORC1 can be maintained once the environmental redox
potential reaches a certain level, because GSH and GSH/GSSG
give similar levels of warfarin inhibition. In human cells, the identity of
26 MAY 2020 x VOLUME 4, NUMBER 10

reduces VKORC1, generating a conformation hindering warfarin binding. (B)
Stoichiometric binding of warfarin explains the change of therapeutic window
(orange and blue shades). The SNP inhibition curves are from Figure 1B. The
dashed line indicates VKORC1 activity inhibited to the same level for the 2 SNPs.

the molecules that directly reduce VKORC1 remains unclear; these
can be either partner proteins36 or small molecules abundant in the
ER, such as GSH.
Using GSH drastically enhances warfarin sensitivity of VKORC1
in vitro, enabling the enzyme kinetics to be characterized within
a realistic warfarin inhibition range (nanomolar). Establishing such
a proper assay system for this highly unstable intramembrane
enzyme has been a major obstacle in the field. Although cellular
carboxylation assays13,16,17,23 provide a native environment for
VKORC1, they are incapable of kinetics characterization because
the carboxylation reporter is an indirect measure of the VKORC1
activity and because the diffusion rates of substrate or warfarin into
the ER are unknown. The kinetics can be characterized by in vitro
assays using detergent-dissolved cells or microsomes.12,25,37-39
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proposed to mediate the antidotal process of vitamin K.23,32
Because warfarin does not inhibit this unknown enzyme, its 30%
contribution can be estimated from the retained carboxylation
activity at high warfarin concentration (double arrow in Figure 5C).
The apparent KM of the unknown enzyme (22.7 mM) is about
50 times higher than that of VKORC1 (0.45 mM) in the cellular
assay (Figure 5E). Thus, the unknown enzyme is a poor K reductase
that has a low activity even at high K concentration (eg, 4 mM). In
contrast, competition at this K concentration can largely restore
VKORC1 activity. To avoid complications from the unknown
enzyme, we measured the warfarin IC50 with varying concentrations
of KO, which cannot be reduced by the unknown enzyme
(supplemental Figure 4). The inhibition curves show that high
concentration of warfarin completely inhibits the total carboxylation
activity that is solely from VKORC1. Importantly, increasing KO is
capable of restoring the VKORC1-mediated carboxylation. Taken
together, competing warfarin off from VKORC1 appears to be
a major route for the vitamin K antidote to restore coagulation.

DTT, however, is traditionally used in these assays, in which warfarin
becomes a poor inhibitor with an IC50 in the micromolar range. This
large discrepancy motivated our discovery that, in presence of the
native GSH reductant, warfarin inhibits microsomal VKORC1 with
a Kiapp in the nanomolar range, similar to that observed in cellular
assays.13,16,17,23

The tight-binding inhibition explains the clinical observation of SNP
21639 G.A (Figure 6B), with which the VKORC1 protein level
and warfarin dose are both lowered. Because dissociation of the
tightly bound warfarin is negligible, active VKORC1 enzyme is
stoichiometrically removed by warfarin. Thus, the lower the
VKORC1 level, the lower the warfarin required to inhibit VKORC1.
In other words, the required warfarin dose directly correlates with
the SNP variation that changes cellular VKORC1 level. Furthermore, the stoichiometric inhibition can explain the additive effect
of G.A allele: patients carrying homozygous A alleles require
the lowest warfarin dose and those with heterozygous A allele
require an intermediate dose,8 owing to the cumulative increase of
VKORC1 levels.
The tight-binding mechanism may partly explain the narrow
therapeutic window of warfarin. Whenever the VKORC1 expression
level is exceeded by the warfarin concentration in the liver, all
VKORC1 molecules are inhibited, and warfarin essentially cannot be
released. The complete absence of VKORC1 activity, if sufficiently
prolonged, leads to supratherapeutic anticoagulation and hemorrhage that is observed in some patients. Overall, VKORC1 levels in
different patients are an important factor that may contribute to the
narrow therapeutic window and interindividual variability of warfarin
dosage management.
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